Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

Summary

The investigators do the clinical trial (patients with metastatic nasopharyngeal carcinoma treated with donafenib after failure of standard therapy) to assess safety and efficacy of donafenib in patients with metastatic nasopharyngeal carcinoma, progressing after all approved standard therapies.

Timeline

Start

2017-02-08

Primary completion

2021-10-20

Completion

2021-10-20

Drugs

Indications